NxStage Reports Record Fourth Quarter and Full-Year 2013 Financial Results

Highlights:
-- Full-Year Revenue Increases to $263.4 million, 9% Annual Growth
-- Full-Year Home Revenue Increases to $132.9 million, 8% Annual Growth
-- Q4'13 Home Revenue Increases 12% over Q4'12

PR Newswire

LAWRENCE, Mass., Feb. 27, 2014 /PRNewswire/ -- NxStage® Medical, Inc. (NXTM), a leading manufacturer of innovative dialysis products, today reported record financial results for the three and twelve months ended December 31, 2013, that include revenue slightly above its recent guidance.

View photo

.
NxStage Medical, Inc.

NxStage Medical, Inc.

Revenue for the full-year 2013 increased 9 percent to $263.4 million, compared with revenue of $242.1 million for the full-year 2012.  Revenue for the fourth quarter of 2013 increased 7 percent to a record $69.4 million compared with revenue of $65.0 million for the fourth quarter of 2012.  The increase in both periods was led by the Company's solid performance in the Home.

Home delivered 8 percent annual growth, with revenue increasing to $132.9 million for the full-year 2013 compared with revenue of $123.6 million for the full-year 2012.  Home revenue increased to $35.1 million in the fourth quarter of 2013 compared with revenue of $31.4 million in the fourth quarter of 2012, representing a 12 percent increase. 

Critical Care delivered 11 percent annual growth, with revenue increasing to $43.8 million for the full-year 2013 compared with revenue of $39.5 million for the full-year 2012.  Revenue in Critical Care increased to $11.6 million in the fourth quarter of 2013, compared with revenue of $11.3 million in the fourth quarter of 2012, representing a 3 percent increase.

The Company's in-center business, Medisystems, delivered 6 percent annual growth with revenue increasing to $81.9 million for the full-year 2013, compared with revenue of $76.9 million for the full-year 2012.  Fourth quarter 2013 revenue was $20.6 million, compared with $21.5 million in the fourth quarter of 2012.

NxStage reported a net loss of $18.6 million or $(0.31) per share for the full-year 2013 compared with a net loss of $15.2 million or $(0.26) per share for the full-year 2012.  The Company reported a net loss of $5.2 million or $(0.08) per share for the fourth quarter of 2013 compared with a net loss of $2.4 million or $(0.04) per share for the fourth quarter of 2012. The Company's net loss for 2013 reflects a nearly $6 million impact from our market development activities with NxStage Kidney Care.

"At the start of 2013, we placed a major focus on growth and investment to take advantage of the significant opportunity in front of us and create long term shareholder value," stated Jeffrey H. Burbank, Founder and Chief Executive Officer of NxStage. "We made great progress across a number of key areas as evidenced by early positive momentum with our direct to patient marketing and solid execution on our innovation pipeline."

Burbank continued, "Similar to this past year, 2014 will be focused on growth and investment. We remain confident in the strength of our near-term initiatives to achieve our target of 15% annual growth in the Home and are continuing to invest significantly in long-term initiatives to increase patient access to our therapies and accelerate adoption. These initiatives include another robust innovation pipeline with peritoneal dialysis and next generation products, and expanded market development activities with a cadence of one to three additional NxStage Kidney Care centers each quarter in 2014, leading to a total of approximately 10 to 15 centers by the end of this year."

Guidance:

For the full fiscal year 2014, the Company is forecasting revenue to be between $283 and $288 million, and a net loss in the range of $23.0 to $27.0 million or $(0.37) to $(0.44) per share. The Company's net loss guidance includes losses in the range of $15 million related to the Company's investment in NxStage Kidney Care.

For the first quarter of 2014, the Company expects revenue to be in a range of $69.5 and $70.5 million, and a net loss in the range of $6.5 to $7.5 million or $(0.11) to $(0.12) per share.

"We remain committed to maintaining strong financial discipline. Excluding our investment in NxStage Kidney Care, we expect to have positive operating income in 2015. Together with $84 million in cash at year end and a strong balance sheet, I believe that we are well positioned to fund our strategic initiatives to expand the home market," stated Matthew W. Towse, Chief Financial Officer. 

Conference Call:

NxStage will also host a conference call today, Thursday, February 27, 2014, at 9:00 a.m. Eastern Time to discuss its fourth quarter and full-year financial results.  To listen to the conference call, please dial 877-392-9886 (domestic) or 707-287-9329 (international).  The call will also be webcast LIVE and can be accessed via the investor relations section of the Company's website at http://ir.nxstage.com.

A replay of the conference call will be available two hours after the completion of the call through March 7, 2014.  To access the replay, dial 855-859-2056 (domestic) or 404-537-3406 (international) and reference conference ID 31404719.  An online archive of the conference call can be accessed via the investor relations section of the Company's website at http://ir.nxstage.com.

About NxStage

NxStage Medical, Inc. (NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the company's website at www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated demand for the Company's products, anticipated operating results, including revenues, loss, gross margin, and other expectations as to future operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for NxStage's products domestically and internationally, growth in home and/or more frequent hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in reimbursement for home and more frequent hemodialysis, changes in the regulatory environment, changes in the historical purchasing patterns and preferences of our customers, including DaVita Healthcare Partners Inc. and Fresenius Medical Care, including in response to NxStage Kidney Care, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2013.

In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

Contact:

Kristen K. Sheppard, Esq.

VP, Investor Relations

ksheppard@nxstage.com

Non-GAAP Financial Measure

The Company discloses a certain non-GAAP financial measure to supplement the Company's consolidated financial statements presented on a GAAP basis. This non-GAAP measure is not in accordance with, or an alternative for, generally accepted accounting principles in the United States and may be different from similar non-GAAP financial measures used by other companies. The non-GAAP financial measure disclosed by the Company is not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. Management uses Adjusted EBITDA (EBITDA adjusted for stock based-compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses) to understand operational cash usage.  The Company believes the non-GAAP financial measure provides useful and supplementary information allowing investors greater transparency to one measure used by management.  The non-GAAP financial measure is meant to supplement, and to be viewed in conjunction with, GAAP financial measures.  The non-GAAP financial measure is reconciled to the most comparable GAAP financial measure below.

 


NxStage Medical, Inc.

Consolidated Statements of Comprehensive Loss

(in thousands, except per share data)

(unaudited)






Three Months Ended
December 31,


Twelve Months Ended
December 31,



2013


2012


2013


2012









Revenues

$

69,450


$

65,020


$

263,429


$

242,132

Cost of revenues

41,562


39,661


160,926


149,324

Gross profit

27,888


25,359


102,503


92,808

Operating expenses:








Selling and marketing

13,056


10,479


47,842


40,485

Research and development

4,963


4,690


18,887


17,111

Distribution

5,975


5,043


21,246


18,888

General and administrative

8,472


7,057


32,326


27,530

Total operating expenses

32,466


27,269


120,301


104,014

Loss from operations

(4,578)


(1,910)


(17,798)


(11,206)

Other expense:








Interest expense

(149)


(91)


(611)


(2,766)

Other (expense) income, net

(69)


(30)


(397)


(148)


(218)


(121)


(1,008)


(2,914)

Net loss before income taxes

(4,796)


(2,031)


(18,806)


(14,120)

(Benefit from) provision for income taxes

380


333


(245)


1,033

Net loss

$

(5,176)


$

(2,364)


$

(18,561)


$

(15,153)

Net loss per share, basic and diluted

$

(0.08)


$

(0.04)


$

(0.31)


$

(0.26)

Weighted-average shares outstanding, basic and diluted

60,940


59,076


60,261


57,890

Other comprehensive (loss) gain, net of tax

44


(49)


(258)


538

Comprehensive loss

$

(5,132)


$

(2,413)


$

(18,819)


$

(14,615)









 


NxStage Medical, Inc.

Consolidated Balance Sheets

(in thousands, except share data)

(unaudited)






December 31,


2013


2012

ASSETS




Current assets:




Cash and cash equivalents

$

84,134


$

106,439

Accounts receivable, net

20,158


18,990

Inventory

37,801


33,504

Prepaid expenses and other current assets

4,027


2,534

Total current assets

146,120


161,467

Property and equipment, net

52,478


36,320

Field equipment, net

13,041


10,101

Deferred cost of revenues

34,730


38,028

Intangible assets, net

17,194


19,819

Goodwill

41,817


42,421

Other assets

1,582


3,793

Total assets

$

306,962


$

311,949

LIABILITIES AND STOCKHOLDERS' EQUITY




Current liabilities:




Accounts payable

$

14,610


$

16,645

Accrued expenses

21,025


20,400

Current portion of long-term debt

102


Other current liabilities

1,870


2,187

Total current liabilities

37,607


39,232

Deferred revenues

53,277


59,262

Long-term debt

1,044


Other long-term liabilities

20,273


15,864

Total liabilities

112,201


114,358

Commitments and contingencies




Stockholders' equity:




Undesignated preferred stock: par value $0.001, 5,000,000 shares authorized;
       no shares issued and outstanding as of December 31, 2013 and 2012


Common stock: par value $0.001, 100,000,000 shares authorized; 61,666,048 and 
       59,850,117 shares issued as of December 31, 2013 and 2012, respectively

61


59

Additional paid-in capital

567,468


551,594

Accumulated deficit

(363,542)


(344,981)

Accumulated other comprehensive income (loss)

212


470

Treasury stock, at cost: 575,895 and 541,584 shares as of December 31, 2013 and
       2012, respectively

(9,963)


(9,551)

Total NxStage Medical, Inc. stockholders' equity

194,236


197,591

Noncontrolling interest

525


Total stockholders' equity

194,761


197,591

Total liabilities and stockholders' equity

$

306,962


$

311,949





 


NxStage Medical, Inc.

Cash Flows from Operating Activities

(in thousands)

(unaudited)






Twelve Months Ended
December 31,


2013


2012

Cash flows from operating activities:




Net loss

$

(18,561)


$

(15,153)

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:




Depreciation and amortization

24,848


23,673

Stock-based compensation

8,638


11,403

Other

2,628


3,517

Changes in operating assets and liabilities:




Accounts receivable

(1,095)


(3,141)

Inventory

(20,076)


(14,545)

Prepaid expenses and other assets

(484)


(1,623)

Accounts payable

(2,233)


839

Accrued expenses and other liabilities

1,081


5,263

Deferred revenues

(4,887)


(3,992)

Net cash (used in) provided by operating activities

$

(10,141)


$

6,241






 


NxStage Medical, Inc.

Revenues by Segment

(in thousands)

(unaudited)














Three Months Ended
December 31,


Twelve Months Ended
December 31,


2013


2012


2013


2012

System One segment








Home

$

35,148


$

31,418


$

132,944


$

123,589

Critical Care

11,605


11,283


43,812


39,540

Total System One segment

46,753


42,701


176,756


163,129

In-Center segment

20,645


21,450


81,852


76,927

Other

2,052


869


4,821


2,076

Total

$

69,450


$

65,020


$

263,429


$

242,132









 

NxStage Medical, Inc.

Non-GAAP Financial Measures

(in millions)

(unaudited)














Three Months Ended
December 31,


Twelve Months Ended
December 31,


2013


2012


2013


2012









Net loss

$

(5.2)


$

(2.4)


$

(18.6)


$

(15.2)

Less: Depreciation, amortization, interest, and taxes

7.0


6.6


25.6


27.6

Less: Adjusting items*

(4.4)


(2.1)


(8.8)


(4.4)









Adjusted EBITDA

$

(2.6)


$

2.1


$

(1.8)


$

8.0









* Adjusting items include stock-based compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses

 

Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO

 

Rates

View Comments (0)